Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/HCO.0000000000000860 http://scihub22266oqcxt.onion/10.1097/HCO.0000000000000860 33929363!ä!33929363 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33929363.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Curr+Opin+Cardiol 2021 ; 36 (4): 405-412 Nephropedia Template TP {{tp|p=33929363|t=2021. Tailoring the management of hypertension to comorbidities |pdf=|usr=}}{{33929363}} gab.com Text Tailoring the management of hypertension to comorbidities JO: Curr Opin Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33929363 #FOAvip PURPOSE OF REVIEW: In this article, we review the most current evidence for initiation and maintenance of various antihypertension (HTN) drug classes, including other misconceptions with respect to common comorbidities in patients with HTN. RECENT FINDINGS: Although the currently available anti-HTN agents have broad applicability in treating HTN, additional agents, such as angiotensin receptor-neprilysin inhibitors and novel nonsteroidal mineralocorticoid antagonists, have recently gained clinical significance. In addition, there have been some anecdotal concerns regarding the adverse effects, indications, and risks of COVID-19 infection/mortality when using certain anti-HTN agents. SUMMARY: Current guidelines currently address the treatment of primary HTN. However, isolated HTN is uncommon and often involves comorbid diseases that require specific regimentation. Several experimental medications are currently in late-stage trials showing potential superiority over current drugs that are available in the market. Twit Text FOAVip Tailoring the management of hypertension to comorbidities ????Curr Opin Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=33929363 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33929363 #FOAvip English Wikipedia <ref>{{Cite pmid|33929363}}</ref> Tailoring the management of hypertension to comorbidities #MMPMID33929363 Mendoza MF; Kachur SM; Lavie CJ Curr Opin Cardiol 2021[Jul]; 36 (4): 405-412 PMID33929363show ga PURPOSE OF REVIEW: In this article, we review the most current evidence for initiation and maintenance of various antihypertension (HTN) drug classes, including other misconceptions with respect to common comorbidities in patients with HTN. RECENT FINDINGS: Although the currently available anti-HTN agents have broad applicability in treating HTN, additional agents, such as angiotensin receptor-neprilysin inhibitors and novel nonsteroidal mineralocorticoid antagonists, have recently gained clinical significance. In addition, there have been some anecdotal concerns regarding the adverse effects, indications, and risks of COVID-19 infection/mortality when using certain anti-HTN agents. SUMMARY: Current guidelines currently address the treatment of primary HTN. However, isolated HTN is uncommon and often involves comorbid diseases that require specific regimentation. Several experimental medications are currently in late-stage trials showing potential superiority over current drugs that are available in the market. |*COVID-19[MESH] |*Hypertension/drug therapy/epidemiology[MESH] |Antihypertensive Agents/therapeutic use[MESH] |Humans[MESH] |Mineralocorticoid Receptor Antagonists[MESH]Tailoring the management of hypertension to comorbidities (epmc).pdf DeepDyve Pubget Overpricing